These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 22864949

  • 1. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
    Teramoto K, Asada Y, Ozaki Y, Suzumura Y, Nakano Y, Sawai S, Tezuka N, Inoue S, Fujino S.
    Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
    [Abstract] [Full Text] [Related]

  • 2. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N, West Japan Oncology Group.
    Lancet Oncol; 2015 Dec; 16(16):1630-8. PubMed ID: 26522337
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
    Kim HJ, Kim TG, Lee HJ, Kim JH, Lim BH, Seo JW, Kang EM, Lee BU, Ahn YM, Roh YH, Nam SH, Kim BS.
    Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
    [Abstract] [Full Text] [Related]

  • 4. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer.
    Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY.
    Cancer Chemother Pharmacol; 2010 Oct; 66(5):889-97. PubMed ID: 20091311
    [Abstract] [Full Text] [Related]

  • 5. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
    Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
    [Abstract] [Full Text] [Related]

  • 6. Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    Kim YH, Kim JS, Choi YH, In KH, Park HS, Hong DS, Jeong TJ, Lee YY, Nam E, Lee SN, Lee KS, Kim HK.
    Int J Clin Oncol; 2002 Apr; 7(2):114-9. PubMed ID: 12018108
    [Abstract] [Full Text] [Related]

  • 7. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326).
    Belani CP, Fossella F.
    Cancer; 2005 Dec 15; 104(12):2766-74. PubMed ID: 16288485
    [Abstract] [Full Text] [Related]

  • 8. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
    Fischer JR, Griesinger F, Fink T, Salm T, Marseille A, Wolf M.
    Lung Cancer; 2012 Mar 15; 75(3):348-52. PubMed ID: 21908069
    [Abstract] [Full Text] [Related]

  • 9. Randomized phase II trial of two different schedules of docetaxel plus cisplatin as first-line therapy in advanced nonsmall cell lung cancer.
    Park SH, Choi SJ, Kyung SY, An CH, Lee SP, Park JW, Jeong SH, Cho EK, Shin DB, Hoon Lee J.
    Cancer; 2007 Feb 15; 109(4):732-40. PubMed ID: 17211861
    [Abstract] [Full Text] [Related]

  • 10. Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience.
    Kocak M, Mayadagli A, Ozkan A, Parlak C, Demir O, Marti A, Dogan Eren M, Kaya S, Gumus M.
    J BUON; 2007 Feb 15; 12(4):471-6. PubMed ID: 18067204
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC).
    Raez LE, Santos ES, Lopes G, Rosado MF, Negret LM, Rocha-Lima C, Tolba K, Farfan N, Hamilton-Nelson K, Silva O, Roman E.
    Lung Cancer; 2006 Sep 15; 53(3):347-53. PubMed ID: 16844257
    [Abstract] [Full Text] [Related]

  • 12. Docetaxel plus cisplatin and bevacizumab for untreated patients with advanced/metastatic non-squamous non-small-cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group.
    Kentepozidis N, Kotsakis A, Soultati A, Agelaki S, Christophylakis Ch, Agelidou M, Chelis L, Papakotoulas P, Vamvakas L, Zafiriou Z, Samonis G, Georgoulias V.
    Cancer Chemother Pharmacol; 2013 Mar 15; 71(3):605-12. PubMed ID: 23338050
    [Abstract] [Full Text] [Related]

  • 13. Phase II study of epirubicin in combination with weekly docetaxel for patients with advanced NSCLC who have failed or relapsed after the frontline platinum-based chemotherapy.
    Lin CM, Chen CH, Chang JW, Tsao TC.
    Am J Clin Oncol; 2009 Apr 15; 32(2):169-73. PubMed ID: 19307958
    [Abstract] [Full Text] [Related]

  • 14. Phase I/II trial of biweekly docetaxel and cisplatin with concurrent thoracic radiation for stage III non-small-cell lung cancer.
    Iwasaki Y, Ohsugi S, Natsuhara A, Tsubokura T, Harada H, Ueda M, Arimoto T, Hara H, Yamada T, Takesako T, Kohno K, Hosogi S, Nakanishi M, Marunaka Y, Nishimura T.
    Cancer Chemother Pharmacol; 2006 Dec 15; 58(6):735-41. PubMed ID: 16565832
    [Abstract] [Full Text] [Related]

  • 15. Sequential administration of docetaxel followed by cisplatin-vindesine: a pilot study in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
    Rixe O, Gatineau M, Jauffret E, Spano JP, Orcel B, Vannetzel JM, Berille J, Derenne JP, Khayat D.
    Bull Cancer; 2005 Jan 15; 92(1):E1-6. PubMed ID: 15689321
    [Abstract] [Full Text] [Related]

  • 16. A multicenter phase II study of docetaxel and carboplatin combination as front-line treatment in advanced non-small cell lung cancer.
    Giannakakis T, Kakolyris S, Theodoropoulos E, Kouroussis C, Michailakis E, Papadouris S, Tsitoura M, Kalbakis K, Souglakos J, Agelaki S, Vardakis N, Georgoulias V.
    Anticancer Res; 2002 Jan 15; 22(6B):3743-8. PubMed ID: 12552987
    [Abstract] [Full Text] [Related]

  • 17. Induction chemotherapy with triweekly docetaxel and cisplatin followed by concomitant chemoradiotherapy with or without surgery in stage III non-small-cell lung cancer: a phase II study.
    Aydiner A, Sen F, Saglam EK, Oral EN, Eralp Y, Tas F, Toker A, Dilege S.
    Clin Lung Cancer; 2011 Sep 15; 12(5):286-92. PubMed ID: 21729649
    [Abstract] [Full Text] [Related]

  • 18. Docetaxel and cisplatin as second-line chemotherapy for advanced non-small cell lung cancer.
    Hamada H, Irifune K, Ito R, Sakai K, Kadowaki T, Katayama H, Abe M, Shiode M, Nishimura K, Higaki J.
    Gan To Kagaku Ryoho; 2007 Aug 15; 34(8):1235-9. PubMed ID: 17687204
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
    Hirose T, Sugiyama T, Kusumoto S, Shirai T, Nakashima M, Yamaoka T, Okuda K, Ogura K, Ohnishi T, Ohmori T, Adachi M.
    Anticancer Res; 2009 May 15; 29(5):1733-8. PubMed ID: 19443395
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of docetaxel-plus-bevacizumab combination therapy in patients previously treated for advanced non-squamous non-small cell lung cancer.
    Ohyanagi F, Yanagitani N, Kudo K, Kawano Y, Sakatani T, Tanimoto A, Nishizawa H, Horiike A, Hagiwara S, Horai T, Nishio M.
    Anticancer Res; 2014 Sep 15; 34(9):5153-8. PubMed ID: 25202107
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.